Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

Conclusions
Longer-term results of this study further support the biosimilarity established between SB11 and RBZ.

Source: British Journal of Ophthalmology - February 20, 2023 Category: Opthalmology Authors: Bressler, N. M., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnicka, J., Vajas, A., Papp, A., Vogt, G., Luu, J., Matuskova, V., Yoon, Y. H., Pregun, T., Kim, T., Shin, D., Oh, I., Jeong, H., Kim, M. Y., Woo, S. J. Tags: Open access, Editor's choice Original articles - Clinical science Source Type: research